Results 71 to 80 of about 1,306,054 (295)
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Frontiers in Pharmacology, 2021 Cancer treatment is a significant challenge for the global health system, although various pharmacological and therapeutic discoveries have been made.
Wenjing Xiao +11 more
doaj +1 more source
, 2018 Epigenetika je znanost koji se bavi proučavanjem epigenoma, odnosno, proučava mehanime aktivacije i supresije određenih gena bez promjene na molekuli DNA.
Šimatović, Domagoj
core
Epigenetic engineering and the art of epigenetic manipulation [PDF]
, 2014 This short and focused meeting was set up to bring the audience up to date with a specific set of techniques broadly categorized as epigenetic engineering (or epigenetic editing).
Magnani, L, Luca Magnani
core +1 more source
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
Molecular Oncology, EarlyView.The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug
Frontiers in Pharmacology, 2021 Cancer is a major global health challenge for our health system, despite the important pharmacological and therapeutic discoveries we have seen since past 5 decades.
Wen-min Zhou +5 more
doaj +1 more source
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
Cells, 2019 Glioma is the most common primary tumor of the nervous system, and approximately 50% of patients exhibit the most aggressive form of the cancer, glioblastoma.
Muhammad Nadeem Abbas +4 more
doaj +1 more source
Journal of Enzyme Inhibition and Medicinal Chemistry, 2023 Androgen deprivation therapy (ADT) is a common treatment for recurrent prostate cancer (PC). However, after a certain period of responsiveness, ADT resistance occurs virtually in all patients and the disease progresses to lethal metastatic castration ...
Aide Negri +5 more
doaj +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Immortality, but not oncogenic transformation, of primary human cells leads to epigenetic reprogramming of DNA methylation and gene expression [PDF]
, 2014 Tumourigenic transformation of normal cells into cancer typically involves several steps resulting in acquisition of unlimited growth potential, evasion of apoptosis and non-responsiveness to growth inhibitory signals. Both genetic and epigenetic changes
de Las Heras, Jose Ignacio +6 more
core +1 more source